Klein J L, Rey P M, Dansey R D, Karanes C, Du W, Abella E, Cassells L, Hamm C, Peters W P, Baynes R D
Barbara Ann Karmanos Cancer Center, Wayne State University School of Medicine, Division of Hematology and Oncology, Detroit, Michigan, USA.
Bone Marrow Transplant. 2000 May;25(10):1047-52. doi: 10.1038/sj.bmt.1702394.
Doxorubicin plus paclitaxel has been shown to be an active regimen for metastatic breast cancer and is now frequently used as adjuvant therapy for high-risk primary breast cancer. Initial studies reported a higher than expected rate of cardiac toxicity with this regimen. We studied 105 patients with either high-risk primary breast cancer or metastatic breast cancer who were treated with doxorubicin (60 mg/m2) and 3-h infusions of paclitaxel (175 mg/m2) cycled every 3 weeks. Patients received three cycles of chemotherapy for high-risk primary or four cycles for metastatic disease. Patients then proceeded to high-dose chemotherapy (HDC) (STAMP I cyclophosphamide, cisplatin and carmustine) and peripheral blood progenitor cell transplantation (PBPCT). Patients underwent radionuclide multi-gated angiograms (MUGA) before and following induction chemotherapy and following HDC. During induction chemotherapy 40 (38%) of the patients had a reduction in left ventricular ejection fraction (LVEF). Fourteen had a decrease of 20% or greater and two were mildly symptomatic from CHF. There was additional reduction in the LVEF after HDC with a median value for LVEF of 59% (range, 20-78%). During HDC 10 patients developed clinical signs of congestive heart failure (CHF). Five patients responded to diuretic therapy and did not require any additional treatment. Four patients responded to vasodilation and/or digoxin with improvement in cardiac function. A clinically significant decrease in cardiac function was found in a small number of patients after induction chemotherapy and HDC with PBPCT. The majority of the patients tolerated this regimen without problems. Although there was a decline in LVEF as measured by radionuclide MUGA this did not prevent the majority of patients from proceeding with HDC. Bone Marrow Transplantation (2000).
多柔比星联合紫杉醇已被证明是转移性乳腺癌的有效治疗方案,目前常用于高危原发性乳腺癌的辅助治疗。初步研究报告称,该方案的心脏毒性发生率高于预期。我们研究了105例高危原发性乳腺癌或转移性乳腺癌患者,这些患者接受多柔比星(60mg/m²)治疗,并每3周进行一次3小时的紫杉醇(175mg/m²)静脉输注。高危原发性乳腺癌患者接受三个周期的化疗,转移性疾病患者接受四个周期的化疗。然后患者接受大剂量化疗(HDC)(STAMP I环磷酰胺、顺铂和卡莫司汀)和外周血祖细胞移植(PBPCT)。患者在诱导化疗前后以及HDC后接受放射性核素多门控血管造影(MUGA)检查。在诱导化疗期间,40例(38%)患者的左心室射血分数(LVEF)下降。14例患者下降了20%或更多,2例因心力衰竭出现轻度症状。HDC后LVEF进一步下降,LVEF的中位数为59%(范围为20%-78%)。在HDC期间,10例患者出现充血性心力衰竭(CHF)的临床症状。5例患者对利尿剂治疗有反应,无需任何额外治疗。4例患者对血管扩张和/或地高辛治疗有反应,心功能改善。少数患者在诱导化疗和HDC及PBPCT后出现了具有临床意义的心脏功能下降。大多数患者耐受该方案无问题。尽管放射性核素MUGA测量显示LVEF有所下降,但这并未阻止大多数患者进行HDC。《骨髓移植》(2000年)